Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAUL R MENA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1609892256
CMS profile
118905
Location
BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$44.07

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $44.07 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $22.68 1
E.R. Squibb & Sons, L.L.C. $21.39 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAUL R MENA

NPI 1609892256 · CMS profile ID 118905

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BURBANK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAUL R MENA, NPI 1609892256, CMS profile ID 118905. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAUL R MENA, NPI 1609892256, CMS profile ID 118905, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1609892256?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $44.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $21.3903/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932484913 CMS
Seagen Inc. $22.6803/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904116569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $165.85 10
PY2021 $62.94 6
PY2022 $44.07 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $175.09 1
PY2024 Principal investigator $3,280.00 3
PY2023 Principal investigator $10,185.60 2
PY2022 Recipient $6,880.00 1
PY2022 Principal investigator $325,752.17 18
PY2021 Recipient $18.75 1
PY2021 Principal investigator $395,903.61 24
PY2020 Recipient $1,784.80 2
PY2020 Principal investigator $859,478.43 105
PY2019 Recipient $4,319.40 2
PY2019 Principal investigator $2,023,210.35 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $1,962.89 12/31/2021 Non-covered Recipient Entity
ROY AND PATRICIA DISNEY FAMILY CANCER CENTER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer KEYNOTE-355 No dispute reported 06/30/2026 848745745
Principal investigator 1 Merck Sharp & Dohme Corporation $66,962.42 12/31/2021 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 848754423
Principal investigator 1 Merck Sharp & Dohme Corporation $10,805.06 12/31/2021 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER, DISNEY FAMILY CANCER
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab LYNK-003. No dispute reported 06/30/2026 848754509
Principal investigator 1 Merck Sharp & Dohme Corporation $25,334.46 12/31/2021 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer No dispute reported 06/30/2026 848754683
Principal investigator 1 Merck Sharp & Dohme Corporation $21,237.07 12/31/2021 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 848754745
Principal investigator 1 Merck Sharp & Dohme Corporation $79,256.54 12/31/2021 Non-covered Recipient Entity
DISNEY FAMILY CANCER CENTER
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 848754779
Principal investigator 1 Merck Sharp & Dohme Corporation $1,875.00 09/27/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC No dispute reported 06/30/2026 848768479
Principal investigator 1 PFIZER INC. $236.17 08/18/2021 Non-covered Recipient Entity
Disney Family Cancer Center
A 6WEEK RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA FOLLOWED BY AN 18WEEK OPENLABEL TREATMENT PERIOD No dispute reported 06/30/2026 948971463
Principal investigator 1 Seagen Inc. $187.50 08/17/2021 Non-covered Recipient Entity
PROVIDENCE ST JOSEPH MEDICAL CENTER
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 792667459
Principal investigator 1 GlaxoSmithKline, LLC. $31,014.00 08/11/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809512225
Principal investigator 1 GlaxoSmithKline, LLC. $62,530.00 08/11/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809512255
Principal investigator 1 Eli Lilly and Company $1,720.00 07/21/2021 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A PHASE 2 STUDY OF LY2784544 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS No dispute reported 06/30/2026 819467061
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $259.00 07/15/2021 Non-covered Recipient Entity
PROVIDENCE TARZANA PHARMACY
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 786500089
Principal investigator 1 GlaxoSmithKline, LLC. $9,304.20 05/21/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809491423
Recipient Eli Lilly and Company $18.75 03/25/2021 Covered Recipient Physician A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819445043
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $370.50 03/16/2021 Non-covered Recipient Entity
PROVIDENCE TARZANA PHARMACY
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 786500087
Principal investigator 1 Merck Sharp & Dohme Corporation $2,800.00 02/24/2021 Non-covered Recipient Entity
PROVIDENCE SAINT JOSEPH MEDICAL CENTER
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 848747443
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $370.50 02/16/2021 Non-covered Recipient Entity
PROVIDENCE TARZANA PHARMACY
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. No dispute reported 06/30/2026 786500085
Principal investigator 1 Genentech, Inc. $1,500.00 01/22/2021 Non-covered Recipient Entity
PROVIDENCE TARZANA MEDICAL CENTER
PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC No dispute reported 06/30/2026 835992631
Principal investigator 1 Incyte Corporation $1,200.00 01/20/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFO
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 831083365
Principal investigator 1 Incyte Corporation $13,750.00 01/20/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM SOUTHERN CALIFO
PROSPECTIVE, NON INTERVENTIONAL STUDY OF DISEASE PROGRESSION AND TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA IN UNITED STATES ACADEMIC OR COMMUNITY CLINICAL PRACTICES No dispute reported 06/30/2026 831083375
Principal investigator 1 GlaxoSmithKline, LLC. $22,360.50 01/19/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809491035
Principal investigator 1 GlaxoSmithKline, LLC. $11,694.00 01/14/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809491447
Principal investigator 1 GlaxoSmithKline, LLC. $13,888.80 01/14/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 809509443
Principal investigator 1 Eli Lilly and Company $15,285.00 01/12/2021 Non-covered Recipient Entity
PROVIDENCE HEALTH SYSTEM
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 819463205